Cargando…
1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
BACKGROUND: Antimicrobial resistance to gram negative organisms is an increasing issue worldwide, particularly with regards to extended-spectrum B-lactamase (ESBL) and carbapenem-resistant Enterobacteriaeceae (CRE) producing organisms. Meropenem/vaborbactam (M-V) is an approved antimicrobial for tre...
Autores principales: | Misikir, Helina, Mulugeta, Surafel, Shallal, Anita, Zervos, Marcus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777637/ http://dx.doi.org/10.1093/ofid/ofaa439.1798 |
Ejemplares similares
-
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018) -
Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023) -
1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018) -
2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019) -
The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)